- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Platinum Responsive Malignancies
- Interventions
- KML-001, Cisplatin
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 7,390
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Cancer, Lymphoma
- Interventions
- NC-4016
- Drug
- Lead sponsor
- NanoCarrier Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- Clofarabine, Mitoxantrone, Etoposide
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Lung Injury, Acute
- Interventions
- SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg, SB-681323 Intravenous 10mg, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Lexington, Kentucky • Durham, North Carolina • Winston-Salem, North Carolina + 3 more
- Conditions
- Spasticity
- Interventions
- Corabotase, Placebo, Dysport
- Biological · Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 5
- States / cities
- Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more
- Conditions
- Kidney Cancer, Renal Cell Carcinoma
- Interventions
- Cabozantinib, Nivolumab, Cytoreductive nephrectomy
- Drug · Procedure
- Lead sponsor
- Mark Stein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 4
- States / cities
- New Brunswick, New Jersey • New York, New York • Cleveland, Ohio + 1 more
- Conditions
- Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Ovarian Cancer
- Interventions
- Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Madison, Wisconsin
- Conditions
- Hypertension, Pulmonary
- Interventions
- Tadalafil, Placebo, ERA as specific PAH treatment
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
- Conditions
- Alzheimer's Disease and Related Dementias
- Interventions
- PES-4-BPSD Model, The attention control condition
- Behavioral
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Glen Oaks, New York • Manhasset, New York
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
- Interventions
- SY-1365 (Part 1), Carboplatin, Fulvestrant, SY-1365 (Cohort 2), SY-1365 (Cohort 5), SY-1365 (Part 2 Single Agent)
- Drug
- Lead sponsor
- Syros Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Francisco, California + 11 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 3
- States / cities
- Westwood, Kansas • Charlotte, North Carolina • Madison, Wisconsin
- Conditions
- Crohn's Disease, Ulcerative Colitis
- Interventions
- Zasocitinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Glen Burnie, Maryland • Tyler, Texas
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Interventions
- LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more
- Conditions
- Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
- Interventions
- LY3009120 capsule
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Houston, Texas
- Conditions
- HIV/AIDS, Adherence, Medication
- Interventions
- Digital Pill
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hypertriglyceridemia
- Interventions
- REGN1500, placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
- Interventions
- AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Multiple Myeloma
- Interventions
- carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Solid Tumors
- Interventions
- STA 9090 (ganetespib)
- Drug
- Lead sponsor
- Synta Pharmaceuticals Corp.
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Detroit, Michigan
- Conditions
- Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
- Interventions
- TSD-001
- Drug
- Lead sponsor
- Lipac Oncology LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
- Conditions
- Acute Pancreatitis
- Interventions
- CM4620
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 3
- States / cities
- Charlotte, North Carolina • Cincinnati, Ohio • Memphis, Tennessee
- Conditions
- HIV Infection
- Interventions
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 48 Hours
- Enrollment
- 1,120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 21
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airway Disease, COPD Exacerbation, Pollution; Exposure, Pollution Related Respiratory Disorder
- Interventions
- Ozone exposure
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2030
- U.S. locations
- 3
- States / cities
- San Francisco, California